Following successive 120 mg doses of gilteritinib in patients with R/R-AML, approximately 90% of FLT3 phosphorylation was decreased, with inhibition starting to take place 24 h after the first dosage [9]. This evidence concerns the gene FLT3 and acute myeloid leukemia.